Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology  |  Pediatrics/Neonatology

Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Leukemia (Pediatric) Clinical Trials

A listing of Leukemia (Pediatric) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (17) clinical trials

Study to Evaluate the Safety Tolerability and Pharmacokinetics of DS-3032b in Hematological Malignancies

This will be a Phase 1, open-label study of DS-3032b to assess its safety and tolerability and identify a Maximum Tolerated Dose (MTD)/tentative Recommended Phase II Dose (RP2D) in subjects with refractory or relapsed Acute Myelogenous Leukemia (AML), Acute Lymphocytic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) in blast phase, or ...

Phase

Safety and Efficacy of Entospletinib With Vincristine and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoid Leukemia (ALL)

This study will evaluate the safety, efficacy, tolerability, and pharmacokinetics of entospletinib (GS-9973) in combination with vincristine (VCR), and dexamethasone in adults with previously treated relapsed or refractory B-cell lineage acute lymphoid leukemia (ALL). This study consists of two parts: Dose Escalation and Dose Expansion. After 2 induction cycles during ...

Phase

Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)

This is a Phase 1 study with ADCT-301 to evaluate the safety, tolerability and pharmacokinetics of ADCT-301 in patients with Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL). ADCT-301 is a human monoclonal antibody attached via a cleavable linker to a pyrrolobenzodiazepine (PBD) warhead which, when internalized by antigen ...

Phase

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Study ADCT-402-102 is the first clinical study with ADCT-402 in patients with B-cell lineage acute lymphoblastic leukemia (ALL). ADCT-402 is an antibody drug conjugate (ADC) composed of a humanized antibody directed against human cluster of differentiation 19 (CD19), stochastically conjugated via a valine-alanine cleavable, maleimide linker to a pyrrolobenzodiazepine (PBD) ...

Phase

Dose Escalation Study to Evaluate the Safety Tolerability and Biological Activity of a Single Dose of UCART19 in Patients With Relapsed / Refractory (R/R) B-cell Acute Lymphoblastic Leukaemia (ALL) and Chronic Lymphocytic Leukaemia (CLL)

The purpose of this study is to evaluate the safety and tolerability of several doses of UCART19 in patient with relapsed / refractory (R/R) acute lymphoblastic leukaemia (ALL) or chronic lymphocytic leukaemia (CLL)

Phase

DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL)

This research study tests an investigational drug called DS-3201b. An investigational drug is a medication that is still being studied and has not yet been approved by the United States Food and Drug Administration (FDA). The FDA allows DS-3201b to be used only in research. It is not known if ...

Phase

Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia

This is a single arm, open-label, multi-center, phase I study to determine the efficacy of CTL019 in patients with r/r B-cell ALL. The study will have the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation & Lymphodepleting Chemotherapy), Treatment and Primary Follow-up, Secondary Follow-up (if applicable) and Survival Follow-up.

Phase

Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib Dasatinib and Prednisone

This is a Phase I, single-center, open label, prospective, single-arm, dose-escalation and multi-dose study evaluating the use of ibrutinib in combination with dasatinib and prednisone therapy.

Phase

Vincristine Sulfate Liposome Injection (Marqibo ) in Combination With UK ALL R3 Induction Chemotherapy for Children Adolescents and Young Adults With Relapsed ALL

This study will utilize Marqibo® as a replacement for standard vincristine in combination with UK ALL R3 induction for children with relapsed ALL. The hypothesis is that the incorporation of Marqibo® with combination chemotherapy will be safe and feasible. In the context of this pilot study, overall outcomes and efficacy ...

Phase

CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphocytic Leukemia

CD19 CAR-T has stronger effect of anti-tumor capacity. While people have been able to control the clinical complications now, so conducting CD19 CAR-T clinical trials has a strong demand and value. The investigators constructed a second generation CAR containing CD137.

Phase